Karyopharm Therapeutics Slides on Disclosure of Cash-retention Program for Executives

Dow Jones

Jul 18

Shares of Karyopharm Therapeutics fell after the company launched a cash-retention program for executives.

The stock slipped 21%, to $7.50, in after-hours trading Friday, after closing up 1.4%, at $9.51. At close, the stock had risen 29% year-to-date.

Under the program, Chief Executive Officer Richard Paulson will receive a cash retention award of more than $1.7 million, the company disclosed in a Friday filing with the Securities and Exchange Commission.

Chief Medical Officer and Head of Research Reshma Rangwala will receive $725,000, Chief Development Officer Stuart Poulton will get $640,000, and Chief Financial Officer Lori Macomber will get $625,000.

"The purpose of the 2026 Leadership Cash Retention Program is to incentivize retention of key employees during a period in which the Company is expecting several meaningful catalysts requiring the continued experience and expertise of the designated employees," the company said in its filing.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

July 17, 2026 18:14 ET (22:14 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2652233925"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2652233925\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2652233925?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-18 06:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652233925","market":"fut","top_or_hot":-1,"title":"Karyopharm Therapeutics Slides on Disclosure of Cash-retention Program for Executives","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Karyopharm <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> fell after the company launched a cash-retention program for executives. \n</p>\n<p>\n  The stock slipped 21%, to $7.50, in after-hours trading Friday, after closing up 1.4%, at $9.51. At close, the stock had risen 29% year-to-date. \n</p>\n<p>\n  Under the program, Chief Executive Officer Richard Paulson will receive a cash retention award of more than $1.7 million, the company disclosed in a Friday filing with the Securities and Exchange Commission. \n</p>\n<p>\n  Chief Medical Officer and Head of Research Reshma Rangwala will receive $725,000, Chief Development Officer Stuart Poulton will get $640,000, and Chief Financial Officer Lori Macomber will get $625,000. \n</p>\n<p>\n  \"The purpose of the 2026 Leadership Cash Retention Program is to incentivize retention of key employees during a period in which the Company is expecting several meaningful catalysts requiring the continued experience and expertise of the designated employees,\" the company said in its filing. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 17, 2026 18:14 ET (22:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Karyopharm Therapeutics Slides on Disclosure of Cash-retention Program for Executives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKaryopharm Therapeutics Slides on Disclosure of Cash-retention Program for Executives\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-18 06:14</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Karyopharm <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> fell after the company launched a cash-retention program for executives. \n</p>\n<p>\n  The stock slipped 21%, to $7.50, in after-hours trading Friday, after closing up 1.4%, at $9.51. At close, the stock had risen 29% year-to-date. \n</p>\n<p>\n  Under the program, Chief Executive Officer Richard Paulson will receive a cash retention award of more than $1.7 million, the company disclosed in a Friday filing with the Securities and Exchange Commission. \n</p>\n<p>\n  Chief Medical Officer and Head of Research Reshma Rangwala will receive $725,000, Chief Development Officer Stuart Poulton will get $640,000, and Chief Financial Officer Lori Macomber will get $625,000. \n</p>\n<p>\n  \"The purpose of the 2026 Leadership Cash Retention Program is to incentivize retention of key employees during a period in which the Company is expecting several meaningful catalysts requiring the continued experience and expertise of the designated employees,\" the company said in its filing. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 17, 2026 18:14 ET (22:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2652233925","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2652233925","pubTimestamp":1784326440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Karyopharm Therapeutics fell after the company launched a cash-retention program for executives.The stock slipped 21%, to $7.50, in after-hours trading Friday, after closing up 1.4%, at $9.51. At close, the stock had risen 29% year-to-date.Under the program, Chief Executive Officer Richard Paulson will receive a cash retention award of more than $1.7 million, the company disclosed in a Friday filing with the Securities and Exchange Commission.Chief Medical Officer and Head of Research Reshma Rangwala will receive $725,000, Chief Development Officer Stuart Poulton will get $640,000, and Chief Financial Officer Lori Macomber will get $625,000.\"The purpose of the 2026 Leadership Cash Retention Program is to incentivize retention of key employees during a period in which the Company is expecting several meaningful catalysts requiring the continued experience and expertise of the designated employees,\" the company said in its filing.Write to Elias Schisgall at elias.schisgall@wsj.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KPTI":"Karyopharm Therapeutics Inc."},"translate_title":"Karyopharm Therapeutics 关于披露高管现金保留计划的幻灯片","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KPTI":1.5},"content_text":"Shares of Karyopharm Therapeutics fell after the company launched a cash-retention program for executives. \n\n\n  The stock slipped 21%, to $7.50, in after-hours trading Friday, after closing up 1.4%, at $9.51. At close, the stock had risen 29% year-to-date. \n\n\n  Under the program, Chief Executive Officer Richard Paulson will receive a cash retention award of more than $1.7 million, the company disclosed in a Friday filing with the Securities and Exchange Commission. \n\n\n  Chief Medical Officer and Head of Research Reshma Rangwala will receive $725,000, Chief Development Officer Stuart Poulton will get $640,000, and Chief Financial Officer Lori Macomber will get $625,000. \n\n\n  \"The purpose of the 2026 Leadership Cash Retention Program is to incentivize retention of key employees during a period in which the Company is expecting several meaningful catalysts requiring the continued experience and expertise of the designated employees,\" the company said in its filing. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 17, 2026 18:14 ET (22:14 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}